SR 5 — RESOLUTION APPROVING THE SETTLEMENT AGREEMENT IN ROBERT BARFIELD, ET AL. V. ANGEL QUIROS, IN HIS OFFICIAL CAPACITY AS COMMISSIONER, CONNECTICUT DEPARTMENT OF CORRECTION.

Senate General Assembly SenateFile Resolution No.

51 January Session, 2021 ReferredSenate toResolution CommitteeNo. on JUDICIARY Introduced by:

(JUD)5 RESOLUTIONSenate, APPROVINGJanuary THE29, SETTLEMENT2021 AGREEMENTThe INSenate ROBERTCommittee BARFIELD,on ETJudiciary AL.reported through SEN.

WINFIELD of the 10th Dist., Chairperson of the Committee on the part of the Senate, that the resolution ought to be adopted.

RESOLUTION APPROVING THE SETTLEMENT AGREEMENT IN ROBERT BARFIELD, ET AL.

JUD Senate Favorable LCOSR5 \\PRDFS1\SCOUSERS\FORZANOF\WS\2021SR-00005-R01/ ofFile 1No. SB.docx

1 1 SR5 File No.

1 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.

In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.

Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note State Impact:

Agency Affected Fund-Effect FY 20 $ FY 21 $ FY 22 $ Correction, Dept.

GF - Cost 7,036,375 20,112,500 10,900,000 Note:

GF=General Fund Municipal Impact:

None Explanation This settlement requires the Department of Correction (DOC) to provide hepatitis C (HCV) screening and treatment to all inmates until March 1, 2022 and pay the fees and costs for the class counsel resulting in the costs described below.

FY 20:

The DOC spent $7.0 million on HCV testing and treatment.

FY 21:

The DOC was appropriated $20 million for HCV testing and treatment and pursuant to the settlement is required to pay $112,500 in attorneys' fees and costs for class counsel.

FY 22:

HVC testing and treatment is anticipated to cost the agency $10.1 million was appropriated for HCV testing and treatment within the Inmate Medical Services (IMS) account in FY 20 and $7.0 million was expended.

The remaining balance was carried forward into FY 21 pursuant to CGS Sec.

4-89(c).

The total carry forward for the IMS account totaled $7.8 million and the entire carry forward may or may not be used for HCV.

2As of 10/31/20 the DOC has spent $2.9 million on HCV testing and treatment in FY 21.

SR5 / File No.

1 2 SR5 File No.

1 approximately $10.9 million until March 1, 2022, which is the end of the settlement agreement.

3 The Out Years None.

3Full-year HCV testing and treatment is estimated to be $18.7 million per year.

SR5 / File No.

1 3